Canaccord Genuity analyst John Newman maintained a Buy rating on Atreca (BCEL) yesterday and set a price target of $23.00. The company’s shares closed last Wednesday at $17.38.
According to TipRanks.com, Newman is a 5-star analyst with an average return of 13.1% and a 43.8% success rate. Newman covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Hutchison China MediTech, and Atara Biotherapeutics.
Currently, the analyst consensus on Atreca is a Strong Buy with an average price target of $27.50, representing a 61.8% upside. In a report issued on April 15, Robert W. Baird also initiated coverage with a Buy rating on the stock with a $30.00 price target.
See today’s analyst top recommended stocks >>
Based on Atreca’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $20.11 million. In comparison, last year the company had a GAAP net loss of $11.98 million.
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BCEL in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman in June 11, 2010 and is headquartered in Redwood, CA.
